Sight Sciences, Inc. (NASDAQ:SGHT) Given Average Recommendation of “Hold” by Brokerages

Sight Sciences, Inc. (NASDAQ:SGHT) has been assigned an average recommendation of “Hold” from the seven brokerages that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $4.70.

SGHT has been the topic of several analyst reports. Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a research report on Friday. Piper Sandler reaffirmed a “neutral” rating and set a $6.00 target price (up from $5.00) on shares of Sight Sciences in a research report on Friday.

Insiders Place Their Bets

In related news, CFO Alison Bauerlein sold 10,123 shares of the stock in a transaction that occurred on Wednesday, April 3rd. The stock was sold at an average price of $5.08, for a total transaction of $51,424.84. Following the sale, the chief financial officer now directly owns 426,248 shares in the company, valued at approximately $2,165,339.84. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, CEO Paul Badawi sold 12,571 shares of Sight Sciences stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $5.08, for a total transaction of $63,860.68. Following the transaction, the chief executive officer now owns 5,750,729 shares of the company’s stock, valued at approximately $29,213,703.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Alison Bauerlein sold 10,123 shares of the business’s stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $5.08, for a total transaction of $51,424.84. Following the completion of the transaction, the chief financial officer now directly owns 426,248 shares of the company’s stock, valued at approximately $2,165,339.84. The disclosure for this sale can be found here. Insiders sold a total of 34,129 shares of company stock worth $173,375 over the last quarter. Company insiders own 27.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC grew its holdings in shares of Sight Sciences by 180.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 12,076 shares of the company’s stock worth $62,000 after purchasing an additional 7,764 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Sight Sciences by 51.9% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,653 shares of the company’s stock valued at $141,000 after purchasing an additional 9,106 shares during the last quarter. Boston Partners raised its holdings in Sight Sciences by 3.1% in the 3rd quarter. Boston Partners now owns 331,776 shares of the company’s stock valued at $1,117,000 after buying an additional 9,919 shares during the last quarter. Swiss National Bank increased its position in Sight Sciences by 19.5% in the 3rd quarter. Swiss National Bank now owns 69,314 shares of the company’s stock valued at $234,000 after acquiring an additional 11,300 shares during the period. Finally, Federated Hermes Inc. raised its stake in shares of Sight Sciences by 100.0% during the third quarter. Federated Hermes Inc. now owns 60,000 shares of the company’s stock valued at $202,000 after acquiring an additional 30,000 shares during the last quarter. 55.51% of the stock is owned by institutional investors and hedge funds.

Sight Sciences Stock Performance

NASDAQ SGHT opened at $5.96 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 13.29 and a quick ratio of 12.65. Sight Sciences has a 1-year low of $1.04 and a 1-year high of $11.00. The company has a market cap of $295.32 million, a P/E ratio of -5.32 and a beta of 2.73. The stock has a 50-day moving average of $5.11 and a two-hundred day moving average of $4.19.

Sight Sciences (NASDAQ:SGHT) last released its quarterly earnings results on Thursday, March 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.13. The firm had revenue of $18.75 million for the quarter, compared to analyst estimates of $18.70 million. Sight Sciences had a negative return on equity of 42.84% and a negative net margin of 67.18%. During the same quarter last year, the company posted ($0.35) earnings per share. As a group, analysts anticipate that Sight Sciences will post -1.04 EPS for the current year.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.